145 related articles for article (PubMed ID: 23484740)
1. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease.
Kanhai DA; Visseren FL; van der Graaf Y; Schoneveld AH; Catanzariti LM; Timmers L; Kappelle LJ; Uiterwaal CS; Lim SK; Sze SK; Pasterkamp G; de Kleijn DP;
Int J Cardiol; 2013 Oct; 168(3):2358-63. PubMed ID: 23484740
[TBL] [Abstract][Full Text] [Related]
2. Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.
Westerink J; van der Graaf Y; Faber DR; Spiering W; Visseren FL;
Eur J Prev Cardiol; 2012 Aug; 19(4):864-73. PubMed ID: 21724680
[TBL] [Abstract][Full Text] [Related]
3. The risk of resting heart rate on vascular events and mortality in vascular patients.
Bemelmans RH; van der Graaf Y; Nathoe HM; Wassink AM; Vernooij JW; Spiering W; Visseren FL;
Int J Cardiol; 2013 Sep; 168(2):1410-5. PubMed ID: 23305859
[TBL] [Abstract][Full Text] [Related]
4. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
[TBL] [Abstract][Full Text] [Related]
5. The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk.
Weijmans M; van der Graaf Y; de Borst GJ; Asselbergs FW; Cramer MJ; Algra A; Visseren FL;
Am Heart J; 2015 Oct; 170(4):744-752.e2. PubMed ID: 26386798
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases.
Vernooij JW; van der Graaf Y; Visseren FL; Spiering W;
Obesity (Silver Spring); 2012 Oct; 20(10):2118-23. PubMed ID: 22517513
[TBL] [Abstract][Full Text] [Related]
7. The risk of general and abdominal adiposity in the occurrence of new vascular events and mortality in patients with various manifestations of vascular disease.
Kanhai DA; Kappelle LJ; van der Graaf Y; Uiterwaal CS; Visseren FL;
Int J Obes (Lond); 2012 May; 36(5):695-702. PubMed ID: 21712810
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease.
Hillaert MA; Lentjes EG; Kemperman H; van der Graaf Y; Nathoe HM; Beygui F; Montalescot G; Doevendans PA; Wassink AM; van Belle E;
Int J Cardiol; 2013 Sep; 167(5):1929-35. PubMed ID: 22727970
[TBL] [Abstract][Full Text] [Related]
9. Plasma triglyceride levels increase the risk for recurrent vascular events independent of LDL-cholesterol or nonHDL-cholesterol.
van de Woestijne AP; Wassink AM; Monajemi H; Liem AH; Nathoe HM; van der Graaf Y; Visseren FL;
Int J Cardiol; 2013 Jul; 167(2):403-8. PubMed ID: 22265582
[TBL] [Abstract][Full Text] [Related]
10. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease.
Goessens BM; van der Graaf Y; Olijhoek JK; Visseren FL;
J Vasc Surg; 2007 Jan; 45(1):47-54. PubMed ID: 17210381
[TBL] [Abstract][Full Text] [Related]
11. The separate and combined effects of adiposity and cardiometabolic dysfunction on the risk of recurrent cardiovascular events and mortality in patients with manifest vascular disease.
van der Leeuw J; van der Graaf Y; Nathoe HM; de Borst GJ; Kappelle LJ; Visseren FL;
Heart; 2014 Sep; 100(18):1421-9. PubMed ID: 24817441
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease.
Vlek AL; van der Graaf Y; Spiering W; Algra A; Visseren FL;
J Intern Med; 2008 Oct; 264(4):351-60. PubMed ID: 18522685
[TBL] [Abstract][Full Text] [Related]
13. Preoperative oral glucose tolerance testing in vascular surgery patients: long-term cardiovascular outcome.
van Kuijk JP; Dunkelgrun M; Schreiner F; Flu WJ; Galal W; van Domburg RT; Hoeks SE; van Gestel YR; Bax JJ; Poldermans D
Am Heart J; 2009 May; 157(5):919-25. PubMed ID: 19376322
[TBL] [Abstract][Full Text] [Related]
14. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
15. Pre-Operative Plasma Extracellular Vesicle Proteins are Associated with a High Risk of Long Term Secondary Major Cardiovascular Events in Patients Undergoing Carotid Endarterectomy.
Timmerman N; Waissi F; Dekker M; van de Pol QY; van Bennekom J; Schoneveld A; Klein Avink MJM; de Winter RJ; Pasterkamp G; de Borst GJ; de Kleijn DPV
Eur J Vasc Endovasc Surg; 2021 Nov; 62(5):705-715. PubMed ID: 34511318
[TBL] [Abstract][Full Text] [Related]
16. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger JS; Bhatt DL; Steg PG; Steinhubl SR; Montalescot G; Shao M; Hacke W; Fox KA; Berger PB; Topol EJ; Lincoff AM
Am Heart J; 2011 Jul; 162(1):98-105.e1. PubMed ID: 21742095
[TBL] [Abstract][Full Text] [Related]
17. Self-rated health status as a risk factor for future vascular events and mortality in patients with symptomatic and asymptomatic atherosclerotic disease: the SMART study.
Grool AM; van der Graaf Y; Visseren FL; de Borst GJ; Algra A; Geerlings MI;
J Intern Med; 2012 Sep; 272(3):277-86. PubMed ID: 22257088
[TBL] [Abstract][Full Text] [Related]
18. The relation between resting heart rate and cancer incidence, cancer mortality and all-cause mortality in patients with manifest vascular disease.
van Kruijsdijk RC; van der Graaf Y; Bemelmans RH; Nathoe HM; Peeters PH; Visseren FL;
Cancer Epidemiol; 2014 Dec; 38(6):715-21. PubMed ID: 25448083
[TBL] [Abstract][Full Text] [Related]
19. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
[TBL] [Abstract][Full Text] [Related]
20. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
